Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    16391218 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders
Condition: Hepatitis B
Intervention: Drug: Entecavir
2 Unknown  Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
Condition: Hepatocellular Carcinoma
Intervention: Drug: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
3 Recruiting To Study the Effect of Adding on Pegylated Interferon (PEG-INF) Therapy for Patients Diagnosed With Chronic Hepatitis B
Condition: Hepatitis B
Interventions: Drug: PEG-IFN & Nucleos(t)tide analogues;   Drug: Nucleos(t)tide analogues
4 Active, not recruiting A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir
Condition: Chronic Heptitis B
Interventions: Drug: tenofovir disoproxil fumarate;   Drug: Entecavir
5 Completed
Has Results
Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection
Conditions: HIV Infections;   Hepatitis B
Interventions: Drug: Entecavir with continued standard of care antiretroviral therapy;   Drug: continued standard of care with tenofovir in addition to emtricitabine or lamivudine

Study has passed its completion date and status has not been verified in more than two years.